「Radiomics」の手法によるCD8陽性T細胞浸潤の評価を用いた抗PD-1/-L1免疫療法に対する治療反応性の検討:後ろ向きマルチコホート研究【Lancet Oncol】


A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Lancet Oncology 2018年8月14日オンライン版

 Because responses of patients with cancer to immunotherapy can vary in success, innovative predictors of response to treatment are urgently needed to improve treatment outcomes. We aimed to develop and independently validate a radiomics-based biomarker of tumour-infiltrating CD8 cells in patients included in phase 1 trials of anti-programmed cell death protein (PD)-1 or anti-programmed cell death ligand 1 (PD-L1) monotherapy. We also aimed to evaluate the association between the biomarker, and tumour immune phenotype and clinical outcomes of these patients.



Leave a comment

Your email address will not be published.